Warfarin Labeling Change: Genetic Test Firms Anxiously Await FDA Action
This article was originally published in The Gray Sheet
Executive Summary
Genetic test makers are lining up in anticipation of an FDA label change for the blood thinner warfarin that could significantly expand the market for companion diagnostics. They might still have a while to wait